Results of univariate and multivariate analysis of relapse among 738 patients with Ph+ ALL
| Variable . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| RR (95% Cl) . | P . | RR (95% Cl) . | P . | |
| Imatinib use before SCT | ||||
| No | 1 (Reference) | 1 (Reference) | ||
| Yes | 0.52 (0.39-0.71) | <.001 | 0.66 (0.43-0.99) | .048 |
| Age at SCT (years) | ||||
| ≤29 | 1 (Reference) | 1 (Reference) | ||
| 30-54 | 0.58 (0.42-0.81) | .001 | 0.63 (0.45-0.89) | .009 |
| ≥55 | 0.60 (0.36-1.03) | .062 | 0.71 (0.40-1.30) | .250 |
| HLA disparity | ||||
| Matched | 1 (Reference) | 1 (Reference) | ||
| Mismatched | 0.52 (0.3-0.74) | <.001 | 0.48 (0.29-0.80) | .005 |
| Stem cell source | ||||
| Related bone marrow | 1 (Reference) | |||
| Unrelated bone marrow | 0.50 (0.35-0.70) | <.001 | 0.76 (0.48-1.21) | .251 |
| Related peripheral blood | 0.76 (0.50-1.16) | .202 | 0.91 (0.58-1.42) | .670 |
| Cord blood | 0.51 (0.31-0.84) | .008 | 1.2 (0.58-2.5) | .618 |
| PS at SCT | ||||
| 0 | 1 (Reference) | 1 (Reference) | ||
| 1-4 | 1.038 (0.75-1.44) | .821 | NA | |
| Days from diagnosis to SCT | ||||
| >180 days | 1 (Reference) | 1 (Reference) | ||
| ≤180 days | 0.91 (.68-1.22) | .538 | 1.16 (0.84-1.61) | .366 |
| BCR-ABL subtype | ||||
| Major | 1 (Reference) | 1 (Reference) | ||
| Minor | 0.61 (0.20-1.91) | .400 | NA | |
| Major and minor | 1.22 (0.44-3.39) | .703 | NA | |
| Donor recipient gender match | ||||
| Male-male | 1 (Reference) | 1 (Reference) | ||
| Male-female | 0.95 (0.65-1.40) | .790 | 1.02 (0.69-1.52) | .908 |
| Female-male | 0.59 (0.37-0.93) | .024 | 0.51 (0.32-0.81) | .004 |
| Female-female | 0.49 (0.30-0.80) | .004 | 0.53 (0.33-0.87) | .013 |
| Conditioning regimen | ||||
| Reduced intensity | 1 (Reference) | 1 (Reference) | ||
| Myeloabrative | 1.15 (0.61-2.17) | .675 | 0.95 (0.51-1.79) | .864 |
| WBC at diagnosis | ||||
| <30 000/μL | 1 (Reference) | 1 (Reference) | ||
| ≤30 000/μL | 1.39 (1.03-1.87) | .029 | 1.08 (1.00-1.16) | .057 |
| GVHD prophylaxis | ||||
| CyA/MTX | 1 (Reference) | 1 (Reference) | ||
| Tacrorimus/MTX | 0.56 (0.40-0.77) | <.001 | 0.74 (0.50-1.09) | .135 |
| Cytogenetics | ||||
| t(9;22) only | 1 (Reference) | 1 (Reference) | ||
| Other abnormality | 1.01 (0.65-1.57) | .955 | NA | |
| ABO blood type disparity | ||||
| Match | 1 (Reference) | 1 (Reference) | ||
| Minor | 0.75 (0.49-1.16) | .199 | NA | |
| Major | 0.86 (0.59-1.24) | .413 | NA | |
| Variable . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| RR (95% Cl) . | P . | RR (95% Cl) . | P . | |
| Imatinib use before SCT | ||||
| No | 1 (Reference) | 1 (Reference) | ||
| Yes | 0.52 (0.39-0.71) | <.001 | 0.66 (0.43-0.99) | .048 |
| Age at SCT (years) | ||||
| ≤29 | 1 (Reference) | 1 (Reference) | ||
| 30-54 | 0.58 (0.42-0.81) | .001 | 0.63 (0.45-0.89) | .009 |
| ≥55 | 0.60 (0.36-1.03) | .062 | 0.71 (0.40-1.30) | .250 |
| HLA disparity | ||||
| Matched | 1 (Reference) | 1 (Reference) | ||
| Mismatched | 0.52 (0.3-0.74) | <.001 | 0.48 (0.29-0.80) | .005 |
| Stem cell source | ||||
| Related bone marrow | 1 (Reference) | |||
| Unrelated bone marrow | 0.50 (0.35-0.70) | <.001 | 0.76 (0.48-1.21) | .251 |
| Related peripheral blood | 0.76 (0.50-1.16) | .202 | 0.91 (0.58-1.42) | .670 |
| Cord blood | 0.51 (0.31-0.84) | .008 | 1.2 (0.58-2.5) | .618 |
| PS at SCT | ||||
| 0 | 1 (Reference) | 1 (Reference) | ||
| 1-4 | 1.038 (0.75-1.44) | .821 | NA | |
| Days from diagnosis to SCT | ||||
| >180 days | 1 (Reference) | 1 (Reference) | ||
| ≤180 days | 0.91 (.68-1.22) | .538 | 1.16 (0.84-1.61) | .366 |
| BCR-ABL subtype | ||||
| Major | 1 (Reference) | 1 (Reference) | ||
| Minor | 0.61 (0.20-1.91) | .400 | NA | |
| Major and minor | 1.22 (0.44-3.39) | .703 | NA | |
| Donor recipient gender match | ||||
| Male-male | 1 (Reference) | 1 (Reference) | ||
| Male-female | 0.95 (0.65-1.40) | .790 | 1.02 (0.69-1.52) | .908 |
| Female-male | 0.59 (0.37-0.93) | .024 | 0.51 (0.32-0.81) | .004 |
| Female-female | 0.49 (0.30-0.80) | .004 | 0.53 (0.33-0.87) | .013 |
| Conditioning regimen | ||||
| Reduced intensity | 1 (Reference) | 1 (Reference) | ||
| Myeloabrative | 1.15 (0.61-2.17) | .675 | 0.95 (0.51-1.79) | .864 |
| WBC at diagnosis | ||||
| <30 000/μL | 1 (Reference) | 1 (Reference) | ||
| ≤30 000/μL | 1.39 (1.03-1.87) | .029 | 1.08 (1.00-1.16) | .057 |
| GVHD prophylaxis | ||||
| CyA/MTX | 1 (Reference) | 1 (Reference) | ||
| Tacrorimus/MTX | 0.56 (0.40-0.77) | <.001 | 0.74 (0.50-1.09) | .135 |
| Cytogenetics | ||||
| t(9;22) only | 1 (Reference) | 1 (Reference) | ||
| Other abnormality | 1.01 (0.65-1.57) | .955 | NA | |
| ABO blood type disparity | ||||
| Match | 1 (Reference) | 1 (Reference) | ||
| Minor | 0.75 (0.49-1.16) | .199 | NA | |
| Major | 0.86 (0.59-1.24) | .413 | NA | |
CyA, cyclospoline; NA, not applicable; RR, relative risk.